Chimeric antigen receptor (CAR) T-cell therapy for multiple myeloma

被引：18

作者：

Choi, Taewoong ^{[1
]}

Kang, Yubin ^{[1
]}

机构：

[1] Duke Univ, Div Hematol Malignancies & Cellular Therapy, Med Ctr, Durham, NC USA

来源：

PHARMACOLOGY & THERAPEUTICS | 2022年 / 232卷

关键词：

Multiple myeloma; Chimeric antigen receptor (CAR) T cell therapy; B cell maturation antigen (BCMA); Immunotherapy; MATURATION ANTIGEN; BISPECIFIC ANTIBODY; BONE-MARROW; BCMA; TARGET; EXPRESSION; DESIGN; TACI;

D O I：

10.1016/j.pharmthera.2021.108007

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Although treatment outcomes of multiple myeloma patients have improved significantly during the last two decades, myeloma is still an incurable disease. There are newly emerging immunotherapies to treat multiple myeloma including monoclonal antibodies, antibody-drug conjugate, bispecific antibodies, and chimeric antigen receptor (CAR) T cell therapy. Impressive response rate and clinical efficacy in heavily pretreated myeloma patients led to the FDA approval of the first myeloma CART therapy in March 2021. Among many different targets for myeloma CAR-T therapies, B Cell Maturation Antigen (BCMA) has been the most successful target so far, but other targets which can be used either for single-target or dual-target CAR-Ts are actively being explored. Clinical efficacy and safety of current myeloma CAR-T therapies will be presented here. Potential mechanisms leading to resistance include dearance of CART cells, antigenic escape, and immunosuppressive tumor microenvironment. Novel strategies to enhance myeloma CART will also be described. In this article, we provide a comprehensive review of the current data and the future directions of myeloma CAR-T therapies. (C) 2021 Elsevier Inc. All rights reserved.

引用

页数：9

共 110 条

[1] CAR models: next-generation CAR modifications for enhanced T-cell function [J].

Abate-Daga, Daniel ;

Davila, Marco L. .

MOLECULAR THERAPY-ONCOLYTICS, 2016, 3 :16014

[2] Strategies to Address Chimeric Antigen Receptor Tonic Signaling [J].

Ajina, Adam ;

Maher, John .

MOLECULAR CANCER THERAPEUTICS, 2018, 17 (09) :1795-1815

[3] Antitumor activity of CAR-T cells targeting the intracellular oncoprotein WT1 can be enhanced by vaccination [J].

Akahori, Yasushi ;

Wang, Linan ;

Yoneyama, Motohiro ;

Seo, Naohiro ;

Okumura, Satoshi ;

Miyahara, Yoshihiro ;

Amaishi, Yasunori ;

Okamoto, Sachiko ;

Mineno, Junichi ;

Ikeda, Hiroaki ;

Maki, Takehiro ;

Fujiwara, Hiroshi ;

Akatsuka, Yoshiki ;

Kato, Takuma ;

Shiku, Hiroshi .

BLOOD, 2018, 132 (11) :1134-1145

[4] T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma [J].

Ali, Syed Abbas ;

Shi, Victoria ;

Maric, Irina ;

Wang, Michael ;

Stroncek, David F. ;

Rose, Jeremy J. ;

Brudno, Jennifer N. ;

Stetler-Stevenson, Maryalice ;

Feldman, Steven A. ;

Hansen, Brenna G. ;

Fellowes, Vicki S. ;

Hakim, Frances T. ;

Gress, Ronald E. ;

Kochenderfer, James N. .

BLOOD, 2016, 128 (13) :1688-1700

[5] Updated Results from the Phase I CRB-402 Study of Anti-Bcma CAR-T Cell Therapy bb21217 in Patients with Relapsed and Refractory Multiple Myeloma: Correlation of Expansion and Duration of Response with T Cell Phenotypes [J].

Alsina, Melissa ;

Shah, Nina ;

Raje, Noopur S. ;

Jagannath, Sundar ;

Madduri, Deepu ;

Kaufman, Jonathan L. ;

Siegel, David S. ;

Munshi, Nikhil C. ;

Rosenblatt, Jacalyn ;

Lin, Yi ;

Jakubowiak, Andrzej ;

Jasielec, Jagoda ;

Timm, Alison ;

Turka, Ashley ;

Mao, Pingping ;

Martin, Nathan ;

Campbell, Timothy B. ;

Hege, Kristen ;

Bitter, Hans ;

Petrocca, Fabio ;

Berdeja, Jesus G. .

BLOOD, 2020, 136

[6] Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma [J].

Baumeister, Susanne H. ;

Murad, Joana ;

Werner, Lillian ;

Daley, Heather ;

Trebeden-Negre, Helene ;

Gicobi, Joanina K. ;

Schmucker, Adam ;

Reder, Jake ;

Sentman, Charles L. ;

Gilham, David E. ;

Lehmann, Frederic F. ;

Galinsky, Ilene ;

DiPietro, Heidi ;

Cummings, Kristen ;

Munshi, Nikhil C. ;

Stone, Richard M. ;

Neuberg, Donna S. ;

Soiffer, Robert ;

Dranoff, Glenn ;

Ritz, Jerome ;

Nikiforow, Sarah .

CANCER IMMUNOLOGY RESEARCH, 2019, 7 (01) :100-112

[7] CD38 as an immunotherapeutic target in multiple myeloma [J].

Bonello, Francesca ;

D'Agostino, Mattia ;

Moscvin, Maria ;

Cerrato, Chiara ;

Boccadoro, Mario ;

Gay, Francesca .

EXPERT OPINION ON BIOLOGICAL THERAPY, 2018, 18 (12) :1209-1221

[8] T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma [J].

Brudno, Jennifer N. ;

Maric, Irina ;

Hartman, Steven D. ;

Rose, Jeremy J. ;

Wang, Michael ;

Lam, Norris ;

Stetler-Stevenson, Maryalice ;

Salem, Dalia ;

Yuan, Constance ;

Pavletic, Steven ;

Kanakry, Jennifer A. ;

Ali, Syed Abbas ;

Mikkilineni, Lekha ;

Feldman, Steven A. ;

Stroncek, David F. ;

Hansen, Brenna G. ;

Lawrence, Judith ;

Patel, Rashmika ;

Hakim, Frances ;

Gress, Ronald E. ;

Kochenderfer, James N. .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (22) :2267-+

[9]

Bu De-Xiu, 2018, Oncotarget, V9, P25764, DOI 10.18632/oncotarget.25359

[10] B-cell Maturation Antigen Is a Promising Target for Adoptive T-cell Therapy of Multiple Myeloma [J].

Carpenter, Robert O. ;

Evbuomwan, Moses O. ;

Pittaluga, Stefania ;

Rose, Jeremy J. ;

Raffeld, Mark ;

Yang, Shicheng ;

Gress, Ronald E. ;

Hakim, Frances T. ;

Kochenderfer, James N. .

CLINICAL CANCER RESEARCH, 2013, 19 (08) :2048-2060

← 1 2 3 4 5 6 7 8 9 10 →